Clinical Trials Directory

Trials / Sponsors / InxMed (Shanghai) Co., Ltd.

InxMed (Shanghai) Co., Ltd.

Industry · 12 registered clinical trials — 7 currently recruiting.

StatusTrialPhaseStarted
RecruitingIN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metas
Solid Tumor Cancer, PDAC
Phase 1 / Phase 22026-02-28
RecruitingA Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-
Non-Small Cell Lung Cancer
Phase 32025-09-10
WithdrawnIN10018 Combination Therapy in Previously-treated Solid Tumors
Solid Tumor
Phase 1 / Phase 22025-08-13
RecruitingIN10018 Combination Therapy in Treatment-naïve ES-SCLC
Small Cell Lung Cancer Extensive Stage
Phase 1 / Phase 22023-10-30
RecruitingIN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC
NSCLC
Phase 1 / Phase 22023-07-13
RecruitingIN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer
Pancreatic Cancer
Phase 1 / Phase 22022-12-08
Active Not Recruitinga Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors
Solid Tumor
Phase 1 / Phase 22022-10-12
RecruitingIN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the
Ovarian Cancer Recurrent
Phase 22022-09-06
CompletedIN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients
Locally Advanced or Metastatic Solid Tumors
Phase 1 / Phase 22022-03-10
RecruitingIN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer
Platinum-resistant Ovarian Cancer
Phase 1 / Phase 22020-07-27
CompletedIN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma
Gastric Cancer
Phase 12020-07-09
CompletedIN10018 Monotherapy and Combination Therapy for Metastatic Melanoma
Metastatic Melanoma
Phase 12020-03-16